Shire Plc has taken steps to strengthen its portfolio of drugs for rare diseases with the acquisition of the Nasdaq-listed ViroPharma Inc of the US which has a marketed product for the prophylactic treatment of hereditary angioedema (HAE). The deal is valued at $4.2 billion.
